New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

References

• Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–1056.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525–1536.
   PubMed Web of Science ®Google Scholar
• Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2010;16:86–94.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignancies following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50(Suppl 2):S37–S39.
   PubMed Web of Science ®Google Scholar
• Magenau J, Westervelt P, Khaled S, et al. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:59–65.
   Web of Science ®Google Scholar
• Alatrash G, Thall PF, Valdez BC, et al. Long-term outcomes after treatment with Clofarabine +/- Fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2016;22:1792–1800.
   PubMed Web of Science ®Google Scholar
• Mohthy M, Malard F, Blaise D, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced intensity transplanattion for primary refractory acute myeloid leukemia. Haematologica. 2017;102:184–191.
   PubMed Web of Science ®Google Scholar
• Kroger N, Bornhauser M, Stelljes M, et al. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). Bone Marrow Transplant. 2015;50:1503–1507.
   PubMed Web of Science ®Google Scholar
• Peccatori J, Forcina A, Clerici D, et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia. 2015;29:396–405.
   PubMed Web of Science ®Google Scholar
• Greco R, Lorentino F, Morelli M, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528–1531.
   PubMed Web of Science ®Google Scholar
• Cieri N, Greco R, Crucitti L, et al. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant. 2015;21:1506–1514.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211–1218.
   PubMed Web of Science ®Google Scholar
• Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012;30:4533–4540.
   PubMed Web of Science ®Google Scholar
• Oshikawa G, Yoshioka K, Takahashi Y, et al. Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome. Pathol Oncol Res. 2015;21:1037–1043.
   PubMed Web of Science ®Google Scholar
• Kako S, Kanda Y, Kato J, et al. The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. Hematol Oncol. 2015 Dec 8. [Epub ahead of print]. DOI: 10.1002/hon.2276
   PubMedGoogle Scholar
• Voso MT, Leone G, Piciocchi A, et al. Feasibility of azacitidine as bridge to allogeneic stem cell transplantation in patients with higher-risk MDS or low-blast count AML: results of the BMT-AZA multicenter prospective study [Abstract]. Blood. 2015;126(23):66.
   Web of Science ®Google Scholar
• Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129–139.
   PubMed Web of Science ®Google Scholar
• Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115:107–121.
   PubMed Web of Science ®Google Scholar
• Craddock C, Jilani N, Siddique S, et al. Tolerability and clinical activity of post transplantation Azacitidine in patients allografted for AML treated in the RICAZA trial: Biol Blood Marrow Transplant 2016;22:385–390.
   Google Scholar
• Schroeder T, Frobel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27:1910–1913.
   PubMed Web of Science ®Google Scholar
• Martino M, Fedele R, Moscato T, et al. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Curr Cancer Drug Targets. 2013;13:661–669.
   PubMed Web of Science ®Google Scholar
• De Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420–5431.
   PubMed Web of Science ®Google Scholar
• Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21:1761–1769.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381–389.
   PubMed Web of Science ®Google Scholar
• Czibere A, Bruns I, Kröger N, et al. 5-azacitidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant. 2010;45:872–876.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010;45:627–632.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions–a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant. 2015;21:653–660.
   PubMed Web of Science ®Google Scholar
• Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101:879–883.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [erratum appears in J Clin Oncol. 2009 May 20;27(15):2574]. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Topp M, Stein A, Gokbuget N, et al. Blinatumomab improved overall survival in patients with relapsed or refractory philadelphia negative b-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (tower) [Abstract S149]. EHA annual meeting; 2016. Haematologica. 2016;101:149a.
   Google Scholar
• DeAngelo DJ, Stelljes M, Martinelli G, et al. Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): an ongoing global phase 3 study [Abstract LB2073]. EHA annual meeting; 2016. Haematologica 2016;1012073a
   Google Scholar
• Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578–2584.
   PubMed Web of Science ®Google Scholar
• Buggerato N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up pf phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL) [Abstract]. Blood. 2015;126(23):680–780.
   Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644–3652.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–1221.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843–850.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612–618.
   PubMed Web of Science ®Google Scholar
• Bar M, Wood BL, Radich JP, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014;2014:1–9. [Epub ahead of print 2014 Mar 23]. DOI: 10.1155/2014/421723
   Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–5187.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA) [Abstract]. Blood. 2015;126(23):679–679.
   Web of Science ®Google Scholar
• Bassan R, Masciulli A, Intermesoli T, et al. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica. 2015;100:786–793.
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22:1983–1987.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Imai K, Mizuta S, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51:43–50.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254–1262.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100(7):898–904.
   PubMed Web of Science ®Google Scholar
• Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29:2126–2133.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–1145.
   PubMed Web of Science ®Google Scholar
• Kroger N, Alchalby H, Ditschkowski M, et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis. Blood. 2013;122:392–398.
   Web of Science ®Google Scholar
• Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49:179–184. [Epub ahead of print 2013 Dec 2]. DOI: 10.1038/bmt.2013.173
   PubMed Web of Science ®Google Scholar
• Lebon D, Rubio MT, Legrand F, et al. Ruxolitinib for patients with primary or secondary myelofibrosis before allogeneic hematopoietic stem cell transplantation (allo-HSCT): a retrospective study of the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) [Abstract]. Blood. 2013;122:21–26.
   Web of Science ®Google Scholar
• Hanif A, Hari PN, Atallah CK, et al. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016;51:617–618.
   PubMed Web of Science ®Google Scholar
• Shanavas M, Popat U, Michaelis LC, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant. 2016;22:432–440.
   PubMed Web of Science ®Google Scholar
• Okiyama N, Furumoto Y, Villarroel VA, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2014;134:992–1000.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–2068.
   PubMed Web of Science ®Google Scholar
• Maffini E, Giaccone L, Festuccia M, et al. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. J Hematol Oncol. 2016;9:67.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell tranpslantation for chronic myeloid leukemia. Blood. 2008;112:3500–3507.
   PubMed Web of Science ®Google Scholar
• Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880–1885.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia. 2009;23:190–194.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252–265.
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes (Review). Blood. 2008;112:4371–4383.
   PubMed Web of Science ®Google Scholar
• Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003;17:1707–1712.
   PubMed Web of Science ®Google Scholar
• Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23:7583–7593.
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E, Kroger N, Brummendorf TH, et al. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biol Blood Marrow Transplant. 2010;16:301–310.
   PubMed Web of Science ®Google Scholar
• Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91:663–666.
   PubMed Web of Science ®Google Scholar
• Shanavas M, Messner HA, Kamel-Reid S, et al. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14:87–92.
   PubMed Web of Science ®Google Scholar
• Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:1009–1015.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1):70–80.
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671–3677.
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O’Donnell PV, Sandmaier BM et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279–1287.
   PubMed Web of Science ®Google Scholar
• Martino M, Festuccia M, Fedele R, et al. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opin Biol Ther. 2016;16:347–364.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236–1243.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–1862.
   PubMed Web of Science ®Google Scholar
• Festuccia M, Busca A, Zallio F, et al. Allogeneic stem cell transplantation and brentuximab vedotin in relapsed refractory hodgkin lymphoma: a multicenter experience [Abstract 3677]. EHA annual meeting; 2016. Haematologica 2016;101:3077a.
   Google Scholar
• Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:1864–1868.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560–568.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist. 2015;20:323–328.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1B study (Keynote-013) [Abstract 290]. ASH annual meeting; 2014. Blood. 2014;126 (23):290a.
   Google Scholar
• Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850–852.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28–35.
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–5536.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Anasetti C, Fernandez HF, et al. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Transplant. 2013;19:1087–1093.
   PubMed Web of Science ®Google Scholar
• Michallet M, Socie G, Mohty M, et al. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Exp Hematol. 2013;41:127–133.
   PubMed Web of Science ®Google Scholar
• Pidala J, Roman-Diaz J, Kim J, et al. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011;93:206–212.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Barker JN, Lechner L, et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant. 2014;20:354–360.
   PubMed Web of Science ®Google Scholar
• Dodero A, Spina F, Sarina B, et al. High-dose rituximab in the conditioning regimen before allogeneic stem cell transplantation decreases deaths related to GVHD without affecting the anti-lymphoma effect [Abstract]. Blood. 2013;122:2059.
   Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era [Erratum appears in J Clin Oncol. 2012 May 20.30 (15):1896]. J Clin Oncol. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:901–907.
   PubMed Web of Science ®Google Scholar
• Blaes AH, Cao Q, Wagner JE, et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:287–291.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Wei W, Korbling M, et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014;124:2306–2312.
   PubMed Web of Science ®Google Scholar
• Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:757–766.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Guthrie KA, Rajendran J, et al. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood. 2011;118:1132–1139.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Zwas ST, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41:355–361.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Lange T, Meisner C, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116:1795–1802.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119:6373–6378.
   PubMed Web of Science ®Google Scholar
• Bethge WA, Von HS, Bornhauser M, et al. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. Bone Marrow Transplant. 2012;47:1397–1402.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912–4920.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438–2447.
   PubMed Web of Science ®Google Scholar
• Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119:4101–4107.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst BF, Schetelig J, et al. LBA-6 Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the Pivotal International Phase 2 Study [Abstract]. Blood. 2015;126:LBA–6.
   Web of Science ®Google Scholar
• Jones J, Mato AR, Coutre S, et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy [Abstract]. Blood. 2015;126:715.
   Web of Science ®Google Scholar
• Farina L, Patriarca F, Mazzucchelli M, et al. Allogeneic stem cell transplantation versus B-cell-receptors inhibitors in 17 p deletion and/or refractory chronic lymphocytic leukemia: aretrospective comaparative analysis of ‘real life’ approaches to high risk patients on behalf of Rete Ematologica Lomabarda (REL) and Gruppo Italiano trapianto di Midollo Osseo (GITMO) [Abstract 4695]. ASH annual meeting; 2016. Blood. 2016;128 (22):4695a.
   Google Scholar
• Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011;117:6721–6727.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121:5055–5063.
   PubMed Web of Science ®Google Scholar
• Htut M, D’Souza A, Bruno B, et al. Survival after relapse following tandem allogeneneic vs.tandem autologous hematopoietic cell transplantation (HCT) for myeloma (MM) [Abstract 833]. ASH annual meeting; 2016. Blood 2016;128(22):833a.
   Google Scholar
• Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016;51:492–500.
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104:3361–3363.
   PubMed Web of Science ®Google Scholar
• Kneppers E, Van Der HB, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118:2413–2419.
   PubMed Web of Science ®Google Scholar
• Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1183–1189.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48:403–407.
   PubMed Web of Science ®Google Scholar
• Caballero-Velazquez T, Lopez-Corral L, Encinas C, et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 2013;162:474–482.
   PubMed Web of Science ®Google Scholar
• Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib [erratum appears in Proc Natl Acad Sci U S A. 2004 Aug24;101(34):12777]. PNAS. 2004;101:8120–8125.
   PubMed Web of Science ®Google Scholar
• Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. 2005;106:3293–3299.
   PubMed Web of Science ®Google Scholar
• Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124:1677–1688.
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30:3202–3208.
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Lange PB, et al. A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a Phase II trial. Biol Blood Marrow Transplant. 2015;21:1907–1913.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1737–1743.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Study of Anti-CD19 chimeric antigen receptorT cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma [Abstract 974]. ASH annual meeting; 2016. Blood 2016;128(22):974a.
   Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-Cell Maturation Antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for Multiple Myeloma (MM): initial safety and efficacy from a Phase I study [Abstract 1147]. ASH annual meeting; 2016. Blood. 2016;128 (22): 1147a.
   Google Scholar
• Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129:1380–1388.
   PubMed Web of Science ®Google Scholar